Xenon Pharmaceuticals Inc Asset Resilience Ratio

Latest as of December 2025: 35.63%

Xenon Pharmaceuticals Inc asset resilience ratio. Xenon Pharmaceuticals Inc (XENE) has an Asset Resilience Ratio of 35.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Xenon Pharmaceuticals Inc (XENE) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

$349.72 Million
Cash + Short-term Investments

Total Assets

$981.67 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Xenon Pharmaceuticals Inc (2013–2025)

Asset resilience ratio of Xenon Pharmaceuticals Inc from 2013 to 2025. This chart shows how Xenon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Xenon Pharmaceuticals Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Xenon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see XENE asset base.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $349.72 Million 35.63%
Total Liquid Assets $349.72 Million 35.63%

Asset Resilience Insights

  • Very High Liquidity: Xenon Pharmaceuticals Inc maintains exceptional liquid asset reserves at 35.63% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Xenon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Xenon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.57%
Eupraxia Pharmaceuticals Inc
TO:EPRX
Biotechnology 25.13%
Cabio Biotech Wuhan Co Ltd
SHG:688089
Biotechnology 3.60%

Xenon Pharmaceuticals Inc Asset Resilience Ratio by Year (2013–2025)

Xenon Pharmaceuticals Inc asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Xenon Pharmaceuticals Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 35.63% $349.72 Million $981.67 Million -25.04pp
2024-12-31 60.67% $484.19 Million $798.14 Million +9.94pp
2023-12-31 50.73% $489.44 Million $964.80 Million -20.19pp
2022-12-31 70.92% $534.85 Million $754.15 Million +5.17pp
2021-12-31 65.75% $376.09 Million $572.01 Million -4.02pp
2020-12-31 69.77% $131.99 Million $189.19 Million -9.18pp
2019-12-31 78.95% $116.60 Million $147.70 Million +36.84pp
2018-12-31 42.11% $51.55 Million $122.43 Million -8.15pp
2017-12-31 50.26% $23.18 Million $46.12 Million -19.46pp
2016-12-31 69.72% $47.05 Million $67.49 Million --
2015-12-31 0.00% $0.00 $63.95 Million --
2014-12-31 13.74% $12.02 Million $87.42 Million -7.04pp
2013-12-31 20.79% $11.33 Million $54.49 Million --
pp = percentage points

About Xenon Pharmaceuticals Inc

NASDAQ:XENE USA Biotechnology
Market Cap
$2.90 Billion
Market Cap Rank
#4871 Global
#1679 in USA
Share Price
$37.54
Change (1 day)
+3.30%
52-Week Range
$33.49 - $70.96
All Time High
$70.96
About

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more